Donaldson completed the acquisition of Univercells Technologies from Gamma Biosciences for €136m.

Donaldson, a provider of innovative filtration products and solutions, completed the acquisition of Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, from Gamma Biosciences, a life sciences platform created by KKR, €136m. "We are delighted that UT will join Donaldson as it expands its presence in biomanufacturing, leveraging its legacy of filtration technology leadership. UT has developed a best-in-class platform for efficient manufacturing of gene therapies and vaccines and will be well positioned as part of the larger Donaldson organization to support the market going forward," Matt Gunnison, Gamma Biosciences CEO.